Handelsbanken Fonder AB bought a new position in shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) during the 4th quarter, Holdings Channel reports. The firm bought 21,500 shares of the biotechnology company’s stock, valued at approximately $1,196,000.
A number of other institutional investors and hedge funds also recently made changes to their positions in SRPT. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Sarepta Therapeutics by 39.5% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,448 shares of the biotechnology company’s stock worth $192,000 after buying an additional 977 shares during the period. Ladenburg Thalmann Financial Services Inc. lifted its stake in shares of Sarepta Therapeutics by 140.9% in the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,262 shares of the biotechnology company’s stock valued at $193,000 after purchasing an additional 2,493 shares during the period. Prentiss Smith & Co. Inc. acquired a new position in shares of Sarepta Therapeutics in the 4th quarter valued at about $199,000. Arrowstreet Capital Limited Partnership acquired a new position in shares of Sarepta Therapeutics in the 4th quarter valued at about $217,000. Finally, Aperio Group LLC acquired a new position in shares of Sarepta Therapeutics in the 4th quarter valued at about $219,000. 84.93% of the stock is currently owned by hedge funds and other institutional investors.
SRPT stock opened at $77.80 on Friday. Sarepta Therapeutics Inc has a 52 week low of $28.14 and a 52 week high of $84.37. The company has a debt-to-equity ratio of 0.54, a quick ratio of 12.96 and a current ratio of 13.91. The firm has a market capitalization of $5,192.42, a P/E ratio of -97.25 and a beta of 1.52.
A number of research analysts have recently issued reports on SRPT shares. BidaskClub raised Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, December 25th. Zacks Investment Research downgraded Sarepta Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, January 5th. HC Wainwright reissued a “buy” rating and issued a $75.00 price objective on shares of Sarepta Therapeutics in a research note on Tuesday, January 9th. JPMorgan Chase & Co. reissued an “overweight” rating and issued a $75.00 price objective (up from $63.00) on shares of Sarepta Therapeutics in a research note on Wednesday, February 21st. Finally, Barclays reissued a “hold” rating and issued a $55.00 price objective on shares of Sarepta Therapeutics in a research note on Tuesday, January 23rd. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. Sarepta Therapeutics has an average rating of “Buy” and an average target price of $76.40.
TRADEMARK VIOLATION WARNING: This piece of content was first posted by Ticker Report and is owned by of Ticker Report. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3295592/handelsbanken-fonder-ab-buys-new-holdings-in-sarepta-therapeutics-inc-srpt.html.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics Inc (NASDAQ:SRPT).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.